Plain-English answers
The GLP-1 questions everyone is actually asking.
Your one-stop guide to GLP-1 peptides — news, dosing tools, and plain-English answers to the questions everyone is actually asking.
Educational content. Not medical advice.
15%
Body weight reduction
Semaglutide STEP-1 trial
22%
Body weight reduction
Tirzepatide SURMOUNT-1 trial
24%
Body weight reduction
Retatrutide TRIUMPH-3 trial
Most asked
Quick answers
Is retatrutide a peptide or a small molecule?
Retatrutide is a peptide — a synthetic chain targeting GLP-1, GIP, and glucagon receptors. Here's what that means for delivery, storage, and cost.
Does retatrutide cause muscle loss?
Retatrutide causes some lean mass loss, as all GLP-1 drugs do. Phase 2 DEXA data shows most weight lost is fat. Protein and resistance training help.
Does tirzepatide work better than Wegovy for weight loss?
Yes. SURMOUNT-5 tested tirzepatide vs. semaglutide 2.4 mg head-to-head over 72 weeks. Tirzepatide won by a meaningful margin. Here's the data.
Does retatrutide work for type 2 diabetes?
Retatrutide works for type 2 diabetes through GLP-1, GIP, and glucagon pathways. Phase 2 data showed blood sugar improvement; TRIUMPH-2 will fill in the A1c detail.
From the blog
Go deeper
Retatrutide and Heart Outcomes: What We'll Know and When
Retatrutide has no cardiovascular outcomes trial yet. What SELECT and SURPASS-CVOT showed — and when retatrutide's CVOT readout is realistically expected.
Should I Wait for Retatrutide? How Doctors Are Counseling
Retatrutide's Phase 2 data looks compelling. But waiting for it means months or years of untreated obesity. Here's how doctors are framing the decision.
Tirzepatide and Bone Density: What We Know and Don't
Tirzepatide drives significant weight loss, but rapid loss can affect bone mineral density. Here's what SURMOUNT data shows and how to protect your bones.
Peptide news
What's happening now
FDA Moves to End Large-Scale GLP-1 Compounding
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk list. The public comment window closes June 29, 2026.
Lilly Previews Retatrutide and Foundayo at ADA 2026
Lilly will present pivotal Phase 3 retatrutide data and new Foundayo results at the ADA's 86th Scientific Sessions in New Orleans, June 5–8, 2026.